Uprima

RSS

apomorphine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Uprima has not been renewed by the marketing authorisation holder and is now withdrawn.

This EPAR was last updated on 29/05/2006

Authorisation details

Product details
Name
Uprima
Agency product number
EMEA/H/C/000327
Active substance
apomorphine hydrochloride
International non-proprietary name (INN) or common name
apomorphine
Therapeutic area (MeSH)
Erectile Dysfunction
Anatomical therapeutic chemical (ATC) code
G04BE
Publication details
Marketing-authorisation holder
Abbott Laboratories Ltd.
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
28/05/2001
Contact address
Queenborough
Kent ME11 5EL
United Kingdom

Product information

29/05/2006 Uprima - EMEA/H/C/000327 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Uprima to be effective, sexual stimulation is required.

How useful was this page?

Add your rating
Average
1 rating